ArticleBMC pregnancy and childbirth2025
A mitochondrial regulator protein, mitofusin 2, is elevated in the maternal blood of women with preeclampsia.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate the expression of mitofusin 2 (Mfn2) in the placenta and peripheral blood of patients with early-onset preeclampsia (eoPE) and late-onset preeclampsia (loPE), and to evaluate its possibility as a diagnostic and therapeutic target for preeclampsia.
methodsA total of 68 pregnant women with preeclampsia in Jiaxing Maternal and Child Health Hospital from June 2022 to June 2024 were selected, including 32 patients with eoPE and 36 patients with loPE, and 68 term pregnant women as negative controls. Real-time fluorescence reverse transcription (RT-qPCR) was used to determine the expression level of Mfn2 mRNA in placenta and peripheral blood, and the expression of Mfn2 was analyzed; enzyme-linked immunosorbent assay (ELISA) was used to determine the level of Mfn2 in peripheral blood of patients, and the outcomes of pregnant women (placental weight, neonatal birth weight, 1 min Apgar) were recorded. The correlation between the level of Mfn2 in peripheral blood and the severity of preeclampsia and pregnancy outcomes was analyzed.
resultThe expression of Mfn2 mRNA in the placenta tissue of the eoPE group was significantly lower than that of the term pregnancy group and the loPE group (P < 0.001), while the expression of Mfn2 in the placenta tissue of the loPE group was only lower than that of the term pregnancy group, with no significant difference(P > 0.05). The expression of Mfn2 mRNA in the peripheral blood of eoPE and loPE was significantly higher than that of term pregnancy group (all P < 0.001). In the peripheral blood, the levels of Mfn2 in eoPE group and loPE group were significantly higher than that of the term pregnancy group (all P < 0.001). The Pearson correlation analysis showed that the expression level of Mfn2 protein in peripheral blood of patients are positively correlated with blood pressure and urinary protein, and negatively correlated with neonatal birth weight and 1 min Apgar score.
conclusionIn early-onset placenta, the expression of Mfn2 is significantly lower than that in full-term pregnancy, while in late-onset eclampsia, it is not, indicating that the abnormal expression of Mnf2 in placenta is related to the occurrence period of preeclampsia and the progression of the disease; Mfn2 in peripheral blood can be used as a biological marker to evaluate the occurrence and progression of preeclampsia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.